Evolocumab in metastatic castration-resistant prostate cancer: study protocol for a single-arm, phase II trial, and initial experience with use of a validated lipid biomarker to direct therapy

Background: Despite advances in the treatment of metastatic castration-resistant prostate cancer (mCRPC), primary and secondary resistance to current therapies remains. Elevated circulating sphingolipids are associated with poor outcomes in patients with mCRPC, including therapeutic resistance and s...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Rhiannon Mellor, Luke Ardolino, Tahlia Scheinberg, Michael Fitzpatrick, Hui-Ming Lin, Paul Bonnitcha, David Sullivan, Peter J. Meikle, Martin R. Stockler, Tania Moujaber, Anthony Joshua, Lisa Horvath
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	SAGE Publishing 2024-12-01
Rangatū:	Therapeutic Advances in Medical Oncology
Urunga tuihono:	https://doi.org/10.1177/17588359241307814
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!